PT  - JOURNAL ARTICLE
AU  - Adler, SO
AU  - Bodeit, O
AU  - Bonn, L
AU  - Goldenbogen, B
AU  - Escalera-Fanjul, X
AU  - Haffner, J
AU  - Karnetzki, M
AU  - Korman, A
AU  - Krantz, M
AU  - Linding, R
AU  - Maintz, I
AU  - Mallis, L
AU  - Moran Torres, RU
AU  - Prawitz, H
AU  - Seeger, M
AU  - Segelitz, P
AU  - Wodke, JAH
AU  - Klipp, E
TI  - Geospatially Referenced Demographic Agent-Based Modeling of SARS-CoV-2-Infection (COVID-19) Dynamics and Mitigation Effects in a Real-world Community
AID  - 10.1101/2020.05.03.20089235
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.03.20089235
4099  - http://medrxiv.org/content/early/2020/05/06/2020.05.03.20089235.short
4100  - http://medrxiv.org/content/early/2020/05/06/2020.05.03.20089235.full
AB  - Re-opening societies and economies across the globe following the initial wave of the severe acute respiratory syndrome–coronavirus 2 (SARS-CoV-2) pandemic requires scientifically-guided decision processes and policy development. Public health authorities now consider it highly likely that transmission of SARS-CoV-2 and COVID-19 will follow a pattern of seasonal circulation globally. To guide mitigation strategies and tactics in a location-specific manner, accurate simulation of prolonged or intermittent patterns of social/physical distancing is required in order to prevent healthcare systems and communities from collapsing. It is equally important to capture the stochastic appearance of individual transmission events. Traditional epidemiological/statistical models cannot make predictions in a geospatial temporal manner based on human individuals in a community. Thus, the challenge is to conduct spatio-temporal simulations of transmission chains with real-world geospatial and georeferenced information of the dynamics of the disease and the effect of different mitigation strategies such as isolation of infected individuals or location closures. Here, we present a stochastic, geospatially referenced and demography-specific agent-based model with agents representing human beings and include information on age, household composition, daily occupation and schedule, risk factors, and other relevant properties. Physical encounters between humans are modeled in a time-dependent georeferenced network of the population. The model (GERDA-1) can predict infection dynamics under normal conditions and test the effect of different mitigation scenarios such as school closures, reduced social contacts as well as closure or reopening of public/work spaces. Specifically, it also includes the fate and influence of health care workers and their access to protective gear. Key predictions so far entail:the effect of specific groups on the spreading, specifically that children in school contribute substantially to distribution.the result of reopening society depends crucially on how strict the measures have been during lock-down.the outcome of reopening is a stochastic process - in the majority of cases, we must expect a second wave, in some cases not. To the best of our best knowledge, the GERDA-1 model is the first model able to predict a bimodal behavior of SARS-Cov-2 infection dynamics.Given the criticality of the global situation, informing the scientific community, decision makers and the general public seems prudent. Therefore, we here provide a pre-print of the GERDA-1 model together with a first set of predictions and analyses as work in progress.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Deutsche Forschungsgemeinschaft (DFG: Cluster of Excellence MATH+, TRR 175) and by the German Ministry of Education and Research (BMBF, Liver Systems Medicine (LiSyM) network grant) and by the People Programme (Marie Skłodowska-Curie Actions) of the European Union’s Horizon 2020 Programme under REA grant agreement no. 813979 (‘Secreters’). Escalera-Fanjul X is supported with a postdoctoral grant from CONACYT (CVU 420248).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe code will be available shortly at https://ford.biologie.hu-berlin.de/tbphu/corona_abm